Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Allodepleted T-cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft-versus-host disease (GVHD) in the absence of GVHD prophylaxis.

Roy DC, Lachance S, Cohen S, Delisle JS, Kiss T, Sauvageau G, Busque L, Ahmad I, Bernard L, Bambace N, Boumédine RS, Guertin MC, Rezvani K, Mielke S, Perreault C, Roy J.

Br J Haematol. 2019 May 28. doi: 10.1111/bjh.15970. [Epub ahead of print]

PMID:
31135970
2.

3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups.

Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, Finke C, Begna KH, Elliott MA, Hook CC, Wolanskyj AP, Patnaik MM, Hanson CA, Ketterling RP, Sirhan S, Pardanani A, Gangat N, Busque L, Tefferi A.

Mayo Clin Proc. 2019 Apr;94(4):599-610. doi: 10.1016/j.mayocp.2018.08.022. Epub 2019 Feb 26.

PMID:
30824279
3.

Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study.

Klil-Drori AJ, Yin H, Azoulay L, Harnois M, Gratton MO, Busque L, Assouline SE; Groupe Québécois de Recherche en Leucémie Myéloïde Chronique et Néoplasies Myéloprolifératives (GQR LMC-NMP).

Haematologica. 2019 Jul;104(7):e293-e295. doi: 10.3324/haematol.2018.211235. Epub 2019 Jan 10. No abstract available.

4.

Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia.

Klil-Drori AJ, Yin H, Azoulay L, Del Corpo A, Harnois M, Gratton MO, Olney HJ, Delage R, Laneuville P, Mollica L, Busque L, Assouline SE; Groupe Québécois de Recherche en Leucémie Myéloïde Chronique et Néoplasies Myéloprolifératives (GQR LMC-NMP).

Cancer. 2019 Feb 15;125(4):618-625. doi: 10.1002/cncr.31835. Epub 2018 Nov 13.

PMID:
30423211
5.

MBD4: guardian of the epigenetic galaxy.

Busque L, Godley LA.

Blood. 2018 Oct 4;132(14):1468-1469. doi: 10.1182/blood-2018-08-867044. No abstract available.

PMID:
30287469
6.

Concise Review: Age-Related Clonal Hematopoiesis: Stem Cells Tempting the Devil.

Busque L, Buscarlet M, Mollica L, Levine RL.

Stem Cells. 2018 Sep;36(9):1287-1294. doi: 10.1002/stem.2845. Epub 2018 Jun 8. Review.

PMID:
29883022
7.

Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host.

Meisel M, Hinterleitner R, Pacis A, Chen L, Earley ZM, Mayassi T, Pierre JF, Ernest JD, Galipeau HJ, Thuille N, Bouziat R, Buscarlet M, Ringus DL, Wang Y, Li Y, Dinh V, Kim SM, McDonald BD, Zurenski MA, Musch MW, Furtado GC, Lira SA, Baier G, Chang EB, Eren AM, Weber CR, Busque L, Godley LA, Verdú EF, Barreiro LB, Jabri B.

Nature. 2018 May;557(7706):580-584. doi: 10.1038/s41586-018-0125-z. Epub 2018 May 16.

8.

Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A.

Buscarlet M, Provost S, Zada YF, Bourgoin V, Mollica L, Dubé MP, Busque L.

Blood. 2018 Jul 19;132(3):277-280. doi: 10.1182/blood-2018-01-829937. Epub 2018 May 15.

9.

Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study.

Perreault S, Shahabi P, Côté R, Dumas S, Rouleau-Mailloux É, Feroz Zada Y, Provost S, Mongrain I, Dorais M, Huynh T, Kouz S, Diaz A, Blostein M, de Denus S, Turgeon J, Ginsberg J, Lelorier J, Lalonde L, Busque L, Kassis J, Talajic M, Tardif JC, Dubé MP.

Clin Cardiol. 2018 May;41(5):576-585. doi: 10.1002/clc.22948. Epub 2018 May 15.

10.

Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies.

Bowman RL, Busque L, Levine RL.

Cell Stem Cell. 2018 Feb 1;22(2):157-170. doi: 10.1016/j.stem.2018.01.011. Review.

11.

Identification of the genetic determinants responsible for retinal degeneration in families of Mexican descent.

Villanueva A, Biswas P, Kishaba K, Suk J, Tadimeti K, Raghavendra PB, Nadeau K, Lamontagne B, Busque L, Geoffroy S, Mongrain I, Asselin G, Provost S, Dubé MP, Nudleman E, Ayyagari R.

Ophthalmic Genet. 2018 Jan-Feb;39(1):73-79. doi: 10.1080/13816810.2017.1373830. Epub 2017 Sep 25.

12.

Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response.

Klil-Drori AJ, Yin H, Azoulay L, Harnois M, Gratton MO, Del Corpo A, Olney HJ, Delage R, Laneuville P, Mollica L, Busque L, Assouline SE; Quebec CML Group.

Am J Hematol. 2017 Oct;92(10):E602-E604. doi: 10.1002/ajh.24838. Epub 2017 Jul 29. No abstract available.

13.

DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions.

Buscarlet M, Provost S, Zada YF, Barhdadi A, Bourgoin V, Lépine G, Mollica L, Szuber N, Dubé MP, Busque L.

Blood. 2017 Aug 10;130(6):753-762. doi: 10.1182/blood-2017-04-777029. Epub 2017 Jun 27.

14.

Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients.

Thiant S, Moutuou MM, Laflamme P, Sidi Boumedine R, Leboeuf DM, Busque L, Roy J, Guimond M.

Blood Cancer J. 2017 Apr 7;7(4):e551. doi: 10.1038/bcj.2017.29.

15.

HSPCs are marathon and not sprint relay athletes.

Busque L.

Blood. 2017 Mar 16;129(11):1406-1407. doi: 10.1182/blood-2017-02-763516. No abstract available.

16.

Clinical-Scale Rapid Autologous BK Virus-Specific T Cell Line Generation From Kidney Transplant Recipients With Active Viremia for Adoptive Immunotherapy.

Lamarche C, Orio J, Georges-Tobar V, Pincez T, Goupil M, Dahmani A, Carli C, Brasey A, Busque L, Delisle JS.

Transplantation. 2017 Nov;101(11):2713-2721. doi: 10.1097/TP.0000000000001698.

PMID:
28230645
17.

Psychological Profiles in the Prediction of Leukocyte Telomere Length in Healthy Individuals.

Starnino L, Busque L, Tardif JC, D'Antono B.

PLoS One. 2016 Oct 27;11(10):e0165482. doi: 10.1371/journal.pone.0165482. eCollection 2016.

18.

Human blood cell levels of 5-hydroxymethylcytosine (5hmC) decline with age, partly related to acquired mutations in TET2.

Buscarlet M, Tessier A, Provost S, Mollica L, Busque L.

Exp Hematol. 2016 Nov;44(11):1072-1084. doi: 10.1016/j.exphem.2016.07.009. Epub 2016 Jul 27.

PMID:
27475703
19.

Laboratory Investigation of Myeloproliferative Neoplasms (MPNs):  Recommendations of the Canadian Mpn Group.

Busque L, Porwit A, Day R, Olney HJ, Leber B, Éthier V, Sirhan S, Foltz L, Prchal J, Kamel-Reid S, Karsan A, Gupta V.

Am J Clin Pathol. 2016 Oct;146(4):408-22. doi: 10.1093/ajcp/aqw131. Review.

PMID:
27686169
20.

Novel germline mutations in the calreticulin gene: implications for the diagnosis of myeloproliferative neoplasms.

Szuber N, Lamontagne B, Busque L.

J Clin Pathol. 2016 Jul 27. pii: jclinpath-2016-203940. doi: 10.1136/jclinpath-2016-203940. [Epub ahead of print]

PMID:
27466382
21.

Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study.

Cortes JE, Lipton JH, Miller CB, Busque L, Akard LP, Pinilla-Ibarz J, Keir C, Warsi G, Lin FP, Mauro MJ.

Clin Lymphoma Myeloma Leuk. 2016 May;16(5):286-96. doi: 10.1016/j.clml.2016.02.002. Epub 2016 Feb 16.

22.

Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation.

Ahmad I, LeBlanc R, Cohen S, Lachance S, Kiss T, Sauvageau G, Roy DC, Busque L, Delisle JS, Bambace N, Bernard L, Sabry W, Roy J.

Bone Marrow Transplant. 2016 Apr;51(4):529-35. doi: 10.1038/bmt.2015.319. Epub 2015 Dec 21.

PMID:
26691426
23.

Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group.

Sirhan S, Busque L, Foltz L, Grewal K, Hamm C, Laferriere N, Laneuville P, Leber B, Liew E, Olney HJ, Prchal J, Porwit A, Gupta V.

Clin Lymphoma Myeloma Leuk. 2015 Dec;15(12):715-27. doi: 10.1016/j.clml.2015.07.650. Epub 2015 Aug 7.

PMID:
26433906
24.

Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.

Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel JP, Brunel JP, Mermel CH, Bass AJ, Pretz J, Ahn J, Hricik T, Kilpivaara O, Wadleigh M, Busque L, Gilliland DG, Golub TR, Ebert BL, Levine RL.

Blood. 2014 May 29;123(22):e123-33. doi: 10.1182/blood-2014-02-554634. Epub 2014 Apr 16.

25.

Safety and cost-effectiveness of outpatient autologous stem cell transplantation in patients with multiple myeloma.

Holbro A, Ahmad I, Cohen S, Roy J, Lachance S, Chagnon M, LeBlanc R, Bernard L, Busque L, Roy DC, Sauvageau G, Kiss TL.

Biol Blood Marrow Transplant. 2013 Apr;19(4):547-51. doi: 10.1016/j.bbmt.2012.12.006. Epub 2012 Dec 16.

26.

Emerging therapeutic options for myelofibrosis: a Canadian perspective.

Gupta V, Foltz L, Sirhan S, Busque L, Turner AR.

Am J Blood Res. 2012;2(3):170-86. Epub 2012 Sep 23.

27.

Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis.

Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, Hamilou Z, Mollica L, Li J, Viale A, Heguy A, Hassimi M, Socci N, Bhatt PK, Gonen M, Mason CE, Melnick A, Godley LA, Brennan CW, Abdel-Wahab O, Levine RL.

Nat Genet. 2012 Nov;44(11):1179-81. doi: 10.1038/ng.2413. Epub 2012 Sep 23.

28.

Tandem autologous-allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity.

Cohen S, Kiss T, Lachance S, Roy DC, Sauvageau G, Busque L, Ahmad I, Roy J.

Biol Blood Marrow Transplant. 2012 Jun;18(6):951-7. doi: 10.1016/j.bbmt.2011.11.028. Epub 2011 Dec 7.

29.

Incidence and prognostic value of eosinophilia in chronic graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation.

Ahmad I, Labbé AC, Chagnon M, Busque L, Cohen S, Kiss T, Lachance S, Roy DC, Sauvageau G, Roy J.

Biol Blood Marrow Transplant. 2011 Nov;17(11):1673-8. doi: 10.1016/j.bbmt.2011.04.012. Epub 2011 May 3.

30.

Cardiac tamponade potentially related to sirolimus following cord blood transplantation.

Holbro A, Ahmad I, Busque L, Cohen S, Lachance S, Roy DC, Roy J, Sauvageau G, Kiss T.

Bone Marrow Transplant. 2012 Feb;47(2):294-5. doi: 10.1038/bmt.2011.44. Epub 2011 Mar 14. No abstract available.

PMID:
21399672
31.

The replication rate of human hematopoietic stem cells in vivo.

Catlin SN, Busque L, Gale RE, Guttorp P, Abkowitz JL.

Blood. 2011 Apr 28;117(17):4460-6. doi: 10.1182/blood-2010-08-303537. Epub 2011 Feb 22.

32.

The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration.

Abdel-Wahab O, Kilpivaara O, Patel J, Busque L, Levine RL.

Leukemia. 2010 Sep;24(9):1656-7. doi: 10.1038/leu.2010.144. Epub 2010 Jul 1. No abstract available.

33.

Late acute renal failure due to bilateral kidney infiltration by ALL as single manifestation of relapse after allogeneic transplantation.

Detrait M, Meunier C, Roy DC, Kiss T, Lachance S, Cohen S, Busque L, Sauvageau G, Roy J.

Bone Marrow Transplant. 2010 May;45(5):953-4. doi: 10.1038/bmt.2009.246. Epub 2009 Sep 21. No abstract available.

PMID:
19767785
34.

Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.

Sabry W, Le Blanc R, Labbé AC, Sauvageau G, Couban S, Kiss T, Busque L, Cohen S, Lachance S, Roy DC, Roy J.

Biol Blood Marrow Transplant. 2009 Aug;15(8):919-29. doi: 10.1016/j.bbmt.2009.04.004. Epub 2009 Jun 10.

35.

No association between telomere length and blood cell counts in elderly individuals.

Mollica L, Fleury I, Belisle C, Provost S, Roy DC, Busque L.

J Gerontol A Biol Sci Med Sci. 2009 Sep;64(9):965-7. doi: 10.1093/gerona/glp065. Epub 2009 May 12.

PMID:
19435952
36.

Skewing of X-inactivation ratios in blood cells of aging women is confirmed by independent methodologies.

Busque L, Paquette Y, Provost S, Roy DC, Levine RL, Mollica L, Gilliland DG.

Blood. 2009 Apr 9;113(15):3472-4. doi: 10.1182/blood-2008-12-195677. Epub 2009 Feb 6.

37.

Diphyllobothriasis, a rare cause of profuse diarrhea following autologous transplantation.

Detrait M, Poirier L, Roy DC, Kiss T, Busque L, Cohen S, Lachance S, Sauvageau G, Roy J.

Bone Marrow Transplant. 2009 Jul;44(2):131-2. doi: 10.1038/bmt.2008.439. Epub 2009 Jan 26. No abstract available.

PMID:
19169286
38.

Differential expression of SMAD3 transcripts is not regulated by cis-acting genetic elements but has a gender specificity.

Busque L, Belisle C, Provost S, Giroux M, Perreault C.

Genes Immun. 2009 Mar;10(2):192-6. doi: 10.1038/gene.2008.101. Epub 2009 Jan 8.

PMID:
19129849
39.

Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms.

Bernard L, Belisle C, Mollica L, Provost S, Roy DC, Gilliland DG, Levine RL, Busque L.

Leukemia. 2009 Feb;23(2):287-91. doi: 10.1038/leu.2008.319. Epub 2008 Nov 13.

40.

Hb Montreal II: a novel elongated beta-globin variant caused by a frameshift mutation [beta142 (-C)].

Chagnon P, Mollica L, Belisle C, Deveaux C, Angelo GD, Roy DC, Soulières D, Busque L.

Hemoglobin. 2008;32(4):351-9. doi: 10.1080/03630260802173593.

PMID:
18654885
41.

Non-traumatic necrosis of bone (osteonecrosis) is associated with endothelial cell activation but not thrombophilia.

Séguin C, Kassis J, Busque L, Bestawros A, Theodoropoulos J, Alonso ML, Harvey EJ.

Rheumatology (Oxford). 2008 Aug;47(8):1151-5. doi: 10.1093/rheumatology/ken206. Epub 2008 Jun 4.

PMID:
18524806
42.

Evidence suggesting the presence of a stem cell clone anteceding the acquisition of the JAK2-V617F mutation.

Jamal R, Bélisle C, Lessard MC, Hébert J, Roy DC, Levine R, Busque L.

Leukemia. 2008 Jul;22(7):1472-4. doi: 10.1038/leu.2008.6. Epub 2008 Jan 31. No abstract available.

43.

No evidence that skewing of X chromosome inactivation patterns is transmitted to offspring in humans.

Bolduc V, Chagnon P, Provost S, Dubé MP, Belisle C, Gingras M, Mollica L, Busque L.

J Clin Invest. 2008 Jan;118(1):333-41.

44.

High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation.

Labbé AC, Su SH, Laverdière M, Pépin J, Patiño C, Cohen S, Kiss T, Lachance S, Sauvageau G, Busque L, Roy DC, Roy J.

Biol Blood Marrow Transplant. 2007 Oct;13(10):1192-200. Epub 2007 Aug 3.

45.

Endothelial-like vascular progenitor cells (VPCs) from allogeneic and autologous donors: mobilization features distinct from hematopoietic progenitors.

Allan DS, Dubé P, Roy J, Busque L, Roy DC.

Biol Blood Marrow Transplant. 2007 Apr;13(4):433-9. Epub 2007 Feb 15.

46.

Prediction of graft-versus-host disease in humans by donor gene-expression profiling.

Baron C, Somogyi R, Greller LD, Rineau V, Wilkinson P, Cho CR, Cameron MJ, Kelvin DJ, Chagnon P, Roy DC, Busque L, Sékaly RP, Perreault C.

PLoS Med. 2007 Jan;4(1):e23.

47.

Overexpression of PRDM16 in the presence and absence of the RUNX1/PRDM16 fusion gene in myeloid leukemias.

Hazourli S, Chagnon P, Sauvageau M, Fetni R, Busque L, Hébert J.

Genes Chromosomes Cancer. 2006 Nov;45(11):1072-6. No abstract available.

48.

Identification and characterization of an Xp22.33;Yp11.2 translocation causing a triplication of several genes of the pseudoautosomal region 1 in an XX male patient with severe systemic lupus erythematosus.

Chagnon P, Schneider R, Hébert J, Fortin PR, Provost S, Belisle C, Gingras M, Bolduc V, Perreault C, Silverman E, Busque L.

Arthritis Rheum. 2006 Apr;54(4):1270-8.

50.

Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation.

Dhédin N, Chamakhi I, Perreault C, Roy DC, Sauvageau G, Ducruet T, Busque L, Fish D, Bélanger R, Roy J.

Exp Hematol. 2006 Jan;34(1):107-14.

PMID:
16413397

Supplemental Content

Loading ...
Support Center